Select 2 to 4 compounds to generate a side-by-side comparison and radar chart.
Loading compounds...
Analyzing the structural and functional differences between Tirzepatide vs. Retatrutide, Semaglutide vs. Cagrilintide, and other GLP-1 agonists.
View comparative data on receptor binding affinity, elimination half-life, and metabolic research profiles. Select two compounds below to visualize differences in chemical stability and subject response markers.
*Retatrutide shows higher metabolic velocity in clinical data.
Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors. Retatrutide is a triple agonist targeting GLP-1, GIP, and the glucagon receptor (GCGR). Research indicates Retatrutide can show higher metabolic velocity in subject models due to inclusion of the glucagon pathway.
Semaglutide is a GLP-1 agonist, while Cagrilintide is a long-acting amylin analog. Research suggests Cagrilintide may show a stronger satiety signaling profile in subject feeding-behavior models compared to GLP-1 agonists alone.